| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Lung Transplantation | 40 | 2021 | 1554 | 6.45 | Why? |
| Bronchiolitis Obliterans | 10 | 2019 | 86 | 2.56 | Why? |
| Primary Graft Dysfunction | 5 | 2018 | 44 | 2.26 | Why? |
| Graft Rejection | 11 | 2018 | 1766 | 1.63 | Why? |
| Delayed Graft Function | 3 | 2019 | 52 | 1.15 | Why? |
| Transplants | 2 | 2021 | 136 | 0.97 | Why? |
| Allografts | 10 | 2019 | 761 | 0.91 | Why? |
| Acetates | 3 | 2018 | 123 | 0.86 | Why? |
| Graft vs Host Reaction | 1 | 2019 | 1 | 0.82 | Why? |
| Tissue Donors | 6 | 2020 | 1679 | 0.74 | Why? |
| Telomere Homeostasis | 1 | 2018 | 52 | 0.74 | Why? |
| Quinolines | 3 | 2018 | 403 | 0.71 | Why? |
| Isoantibodies | 1 | 2017 | 134 | 0.63 | Why? |
| Transplant Recipients | 4 | 2021 | 4982 | 0.62 | Why? |
| Sarcoidosis, Pulmonary | 1 | 2017 | 91 | 0.62 | Why? |
| Interleukin-8 | 4 | 2018 | 964 | 0.62 | Why? |
| Organ Transplantation | 4 | 2021 | 2616 | 0.61 | Why? |
| Lymphoproliferative Disorders | 1 | 2017 | 110 | 0.61 | Why? |
| Bronchoalveolar Lavage | 3 | 2018 | 603 | 0.61 | Why? |
| Myeloid-Derived Suppressor Cells | 1 | 2019 | 316 | 0.59 | Why? |
| HLA Antigens | 2 | 2019 | 830 | 0.58 | Why? |
| Graft Survival | 7 | 2019 | 587 | 0.56 | Why? |
| Postoperative Complications | 7 | 2019 | 5861 | 0.56 | Why? |
| Azithromycin | 4 | 2021 | 3943 | 0.55 | Why? |
| Immune Tolerance | 1 | 2019 | 608 | 0.54 | Why? |
| Radiopharmaceuticals | 1 | 2019 | 763 | 0.53 | Why? |
| Herpesvirus 4, Human | 1 | 2017 | 387 | 0.52 | Why? |
| Sarcoidosis | 1 | 2017 | 271 | 0.52 | Why? |
| Respiratory Insufficiency | 5 | 2021 | 7301 | 0.50 | Why? |
| Bronchiolitis | 1 | 2017 | 297 | 0.50 | Why? |
| Epstein-Barr Virus Infections | 1 | 2017 | 366 | 0.49 | Why? |
| Interleukin-17 | 1 | 2017 | 602 | 0.47 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2019 | 1153 | 0.44 | Why? |
| Belgium | 6 | 2021 | 2064 | 0.44 | Why? |
| Forced Expiratory Volume | 4 | 2019 | 632 | 0.42 | Why? |
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 1458 | 0.38 | Why? |
| Lung | 11 | 2020 | 31049 | 0.38 | Why? |
| Transplantation, Homologous | 5 | 2019 | 757 | 0.36 | Why? |
| Multiple Organ Failure | 1 | 2018 | 1724 | 0.35 | Why? |
| Consensus | 2 | 2019 | 6345 | 0.34 | Why? |
| Airway Obstruction | 1 | 2009 | 182 | 0.33 | Why? |
| Bronchoalveolar Lavage Fluid | 3 | 2019 | 2309 | 0.33 | Why? |
| Interferon-gamma | 1 | 2017 | 2711 | 0.33 | Why? |
| Duodenum | 2 | 2018 | 179 | 0.32 | Why? |
| Anti-Bacterial Agents | 3 | 2021 | 10083 | 0.30 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 1510 | 0.29 | Why? |
| Dietary Supplements | 1 | 2017 | 2251 | 0.27 | Why? |
| Liver Failure | 2 | 2017 | 266 | 0.27 | Why? |
| Sulfides | 3 | 2018 | 113 | 0.25 | Why? |
| Follow-Up Studies | 9 | 2021 | 17020 | 0.25 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2019 | 5837 | 0.23 | Why? |
| Cyclopropanes | 3 | 2018 | 332 | 0.23 | Why? |
| Vitamin D | 1 | 2017 | 2904 | 0.22 | Why? |
| Chronic Disease | 6 | 2019 | 5139 | 0.22 | Why? |
| Gastrointestinal Motility | 2 | 2018 | 78 | 0.21 | Why? |
| Disease Management | 1 | 2019 | 6841 | 0.21 | Why? |
| Itraconazole | 1 | 2021 | 135 | 0.20 | Why? |
| Cytochrome P-450 CYP1A2 Inducers | 1 | 2018 | 2 | 0.20 | Why? |
| Interleukin-6 | 1 | 2018 | 7522 | 0.20 | Why? |
| Cystic Fibrosis | 2 | 2020 | 1104 | 0.20 | Why? |
| Perfusion | 2 | 2017 | 254 | 0.20 | Why? |
| Respiratory Function Tests | 3 | 2018 | 1755 | 0.20 | Why? |
| X-Ray Microtomography | 1 | 2019 | 115 | 0.19 | Why? |
| C-Reactive Protein | 2 | 2021 | 7972 | 0.19 | Why? |
| Telomerase | 1 | 2018 | 45 | 0.19 | Why? |
| Lung Diseases | 3 | 2019 | 2361 | 0.18 | Why? |
| Middle Aged | 28 | 2021 | 270681 | 0.18 | Why? |
| Warm Ischemia | 1 | 2017 | 33 | 0.18 | Why? |
| Prebiotics | 1 | 2018 | 53 | 0.18 | Why? |
| Leukotriene Antagonists | 1 | 2018 | 37 | 0.18 | Why? |
| Neutrophil Activation | 1 | 2021 | 510 | 0.18 | Why? |
| Oligosaccharides | 1 | 2018 | 69 | 0.17 | Why? |
| Hydrochloric Acid | 1 | 2017 | 21 | 0.17 | Why? |
| Freedom | 1 | 2018 | 110 | 0.17 | Why? |
| Telomere Shortening | 1 | 2018 | 66 | 0.17 | Why? |
| Esophageal Sphincter, Lower | 1 | 2017 | 16 | 0.17 | Why? |
| Electrodes, Implanted | 1 | 2017 | 60 | 0.17 | Why? |
| Pleura | 1 | 2019 | 178 | 0.17 | Why? |
| Interleukin-1alpha | 1 | 2017 | 42 | 0.17 | Why? |
| Transforming Growth Factor beta1 | 1 | 2019 | 204 | 0.17 | Why? |
| Tacrolimus | 2 | 2017 | 435 | 0.17 | Why? |
| Adult Stem Cells | 1 | 2017 | 68 | 0.17 | Why? |
| Hunger | 1 | 2018 | 83 | 0.17 | Why? |
| Humans | 53 | 2021 | 930598 | 0.17 | Why? |
| Sildenafil Citrate | 1 | 2017 | 66 | 0.16 | Why? |
| Male | 33 | 2021 | 367725 | 0.16 | Why? |
| Epithelium | 1 | 2019 | 330 | 0.16 | Why? |
| Naltrexone | 1 | 2017 | 56 | 0.16 | Why? |
| Female | 33 | 2021 | 380317 | 0.16 | Why? |
| Adult | 24 | 2021 | 244371 | 0.16 | Why? |
| Postoperative Period | 1 | 2018 | 651 | 0.16 | Why? |
| Mycobacterium Infections, Nontuberculous | 1 | 2019 | 167 | 0.16 | Why? |
| Immunologic Factors | 1 | 2012 | 4206 | 0.15 | Why? |
| Brain Death | 1 | 2017 | 146 | 0.15 | Why? |
| Retrospective Studies | 15 | 2019 | 105322 | 0.15 | Why? |
| Electric Stimulation Therapy | 1 | 2017 | 151 | 0.15 | Why? |
| Dyspepsia | 2 | 2017 | 60 | 0.15 | Why? |
| Voriconazole | 1 | 2017 | 206 | 0.15 | Why? |
| Naloxone | 1 | 2017 | 153 | 0.15 | Why? |
| Cardiomyopathy, Dilated | 1 | 2017 | 251 | 0.14 | Why? |
| Survival Rate | 3 | 2018 | 9206 | 0.13 | Why? |
| Standard of Care | 1 | 2021 | 1297 | 0.13 | Why? |
| Treatment Outcome | 9 | 2021 | 51732 | 0.13 | Why? |
| Anti-Inflammatory Agents | 1 | 2012 | 6153 | 0.13 | Why? |
| Antibodies | 1 | 2019 | 846 | 0.12 | Why? |
| Triazoles | 1 | 2017 | 440 | 0.12 | Why? |
| Narcotic Antagonists | 1 | 2017 | 317 | 0.12 | Why? |
| Multimorbidity | 1 | 2017 | 703 | 0.12 | Why? |
| Stem Cell Transplantation | 1 | 2018 | 531 | 0.12 | Why? |
| Ventilator Weaning | 1 | 2017 | 536 | 0.12 | Why? |
| Superantigens | 1 | 2012 | 53 | 0.12 | Why? |
| Liver Function Tests | 1 | 2018 | 1325 | 0.11 | Why? |
| Idiopathic Pulmonary Fibrosis | 1 | 2018 | 595 | 0.11 | Why? |
| Double-Blind Method | 3 | 2018 | 5988 | 0.11 | Why? |
| Cell Proliferation | 1 | 2019 | 1973 | 0.11 | Why? |
| Toll-Like Receptor 2 | 1 | 2012 | 198 | 0.11 | Why? |
| RNA | 1 | 2018 | 1278 | 0.11 | Why? |
| Dose-Response Relationship, Drug | 2 | 2017 | 3776 | 0.11 | Why? |
| Monocytes | 2 | 2021 | 2978 | 0.10 | Why? |
| Biomarkers | 5 | 2019 | 23361 | 0.10 | Why? |
| Bronchi | 1 | 2017 | 1048 | 0.10 | Why? |
| Renal Insufficiency | 1 | 2017 | 810 | 0.10 | Why? |
| Nitric Oxide | 1 | 2017 | 769 | 0.10 | Why? |
| Prognosis | 6 | 2018 | 32490 | 0.10 | Why? |
| Drug Interactions | 1 | 2017 | 1653 | 0.10 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.10 | Why? |
| Tissue and Organ Procurement | 2 | 2017 | 1277 | 0.10 | Why? |
| Antigens, Bacterial | 1 | 2012 | 330 | 0.10 | Why? |
| Lymphocyte Activation | 1 | 2019 | 2742 | 0.10 | Why? |
| Home Care Services | 1 | 2020 | 1351 | 0.09 | Why? |
| Time Factors | 5 | 2021 | 31397 | 0.09 | Why? |
| Young Adult | 11 | 2021 | 93724 | 0.09 | Why? |
| Pulmonary Fibrosis | 1 | 2018 | 1068 | 0.09 | Why? |
| Proof of Concept Study | 2 | 2021 | 696 | 0.09 | Why? |
| Irritable Bowel Syndrome | 1 | 2011 | 175 | 0.09 | Why? |
| Inflammation | 2 | 2017 | 13255 | 0.09 | Why? |
| Immunomodulation | 1 | 2017 | 1472 | 0.09 | Why? |
| Fatigue Syndrome, Chronic | 1 | 2011 | 160 | 0.09 | Why? |
| Epithelial Cells | 2 | 2017 | 3508 | 0.09 | Why? |
| Vitamins | 1 | 2017 | 1208 | 0.09 | Why? |
| Liver Cirrhosis | 1 | 2018 | 1810 | 0.08 | Why? |
| Parents | 1 | 2020 | 2758 | 0.08 | Why? |
| Staphylococcus aureus | 1 | 2012 | 844 | 0.07 | Why? |
| Resource Allocation | 1 | 2017 | 1771 | 0.07 | Why? |
| Incidence | 2 | 2017 | 25622 | 0.07 | Why? |
| Patient Discharge | 1 | 2021 | 5696 | 0.07 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 5993 | 0.07 | Why? |
| Risk Factors | 7 | 2018 | 71621 | 0.07 | Why? |
| Coronary Artery Disease | 1 | 2019 | 2570 | 0.07 | Why? |
| Health Status | 1 | 2018 | 3259 | 0.07 | Why? |
| Tomography, X-Ray Computed | 4 | 2019 | 25144 | 0.07 | Why? |
| Cross-Over Studies | 2 | 2018 | 867 | 0.07 | Why? |
| Liver | 1 | 2018 | 4007 | 0.07 | Why? |
| Clinical Decision-Making | 1 | 2017 | 3755 | 0.06 | Why? |
| Patient Selection | 1 | 2018 | 4560 | 0.06 | Why? |
| Single-Blind Method | 2 | 2018 | 1283 | 0.06 | Why? |
| Immunosuppressive Agents | 4 | 2018 | 6331 | 0.06 | Why? |
| Venous Thromboembolism | 1 | 2021 | 4273 | 0.06 | Why? |
| Decision Making | 1 | 2017 | 3132 | 0.06 | Why? |
| Case-Control Studies | 2 | 2021 | 17671 | 0.06 | Why? |
| Extracorporeal Membrane Oxygenation | 2 | 2017 | 5002 | 0.06 | Why? |
| Liver Transplantation | 1 | 2017 | 2864 | 0.06 | Why? |
| Registries | 2 | 2018 | 12327 | 0.06 | Why? |
| Biopsy | 2 | 2021 | 2811 | 0.05 | Why? |
| Antigen-Presenting Cells | 1 | 2021 | 206 | 0.05 | Why? |
| In Situ Hybridization, Fluorescence | 1 | 2021 | 207 | 0.05 | Why? |
| Social Isolation | 1 | 2020 | 5932 | 0.05 | Why? |
| Aged | 7 | 2021 | 215776 | 0.05 | Why? |
| Mice | 2 | 2017 | 21357 | 0.05 | Why? |
| Deoxyribonuclease I | 1 | 2019 | 66 | 0.05 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.05 | Why? |
| Myoelectric Complex, Migrating | 1 | 2018 | 1 | 0.05 | Why? |
| Gastrointestinal Transit | 1 | 2018 | 8 | 0.05 | Why? |
| Histocompatibility Antigens Class II | 1 | 2021 | 383 | 0.05 | Why? |
| Respiratory Tract Infections | 1 | 2019 | 6817 | 0.04 | Why? |
| Kaplan-Meier Estimate | 2 | 2018 | 4260 | 0.04 | Why? |
| Manometry | 1 | 2018 | 91 | 0.04 | Why? |
| Nontuberculous Mycobacteria | 1 | 2019 | 114 | 0.04 | Why? |
| Antiviral Agents | 2 | 2021 | 41703 | 0.04 | Why? |
| Receptors, Opioid, mu | 1 | 2017 | 23 | 0.04 | Why? |
| Esophageal pH Monitoring | 1 | 2017 | 33 | 0.04 | Why? |
| Phenotype | 2 | 2019 | 4037 | 0.04 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.04 | Why? |
| Theophylline | 1 | 2017 | 39 | 0.04 | Why? |
| Cyclic GMP | 1 | 2017 | 50 | 0.04 | Why? |
| Cytochrome P-450 CYP3A | 1 | 2017 | 88 | 0.04 | Why? |
| Permeability | 1 | 2017 | 238 | 0.04 | Why? |
| Dapsone | 1 | 2017 | 59 | 0.04 | Why? |
| Azathioprine | 1 | 2017 | 161 | 0.04 | Why? |
| Pulmonary Emphysema | 1 | 2018 | 122 | 0.04 | Why? |
| Tight Junctions | 1 | 2017 | 179 | 0.04 | Why? |
| Blotting, Western | 1 | 2019 | 863 | 0.04 | Why? |
| Phosphodiesterase 5 Inhibitors | 1 | 2017 | 104 | 0.04 | Why? |
| Immunophenotyping | 1 | 2021 | 1290 | 0.04 | Why? |
| Viral Load | 1 | 2017 | 15850 | 0.04 | Why? |
| Aminopyridines | 1 | 2017 | 121 | 0.04 | Why? |
| Dexamethasone | 2 | 2017 | 2055 | 0.04 | Why? |
| Quaternary Ammonium Compounds | 1 | 2017 | 136 | 0.04 | Why? |
| Respiration, Artificial | 2 | 2018 | 22116 | 0.04 | Why? |
| Mycophenolic Acid | 1 | 2017 | 383 | 0.04 | Why? |
| Animals | 4 | 2021 | 78931 | 0.04 | Why? |
| Fluoroquinolones | 1 | 2017 | 235 | 0.04 | Why? |
| Mesocricetus | 1 | 2021 | 1847 | 0.04 | Why? |
| Epithelial-Mesenchymal Transition | 1 | 2017 | 242 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Reoperation | 1 | 2018 | 544 | 0.04 | Why? |
| Spirometry | 1 | 2018 | 524 | 0.03 | Why? |
| Diaphragm | 1 | 2017 | 232 | 0.03 | Why? |
| MAP Kinase Signaling System | 1 | 2017 | 360 | 0.03 | Why? |
| Acetylcysteine | 1 | 2017 | 255 | 0.03 | Why? |
| Critical Care | 1 | 2018 | 14081 | 0.03 | Why? |
| Survival Analysis | 2 | 2018 | 7592 | 0.03 | Why? |
| Benzamides | 1 | 2017 | 421 | 0.03 | Why? |
| Fibrosis | 1 | 2018 | 800 | 0.03 | Why? |
| Cyclosporine | 1 | 2017 | 449 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2021 | 2437 | 0.03 | Why? |
| Microcirculation | 1 | 2017 | 447 | 0.03 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.03 | Why? |
| Phosphorylation | 1 | 2017 | 1060 | 0.03 | Why? |
| Coronary Artery Bypass | 1 | 2019 | 629 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.03 | Why? |
| Extracellular Traps | 1 | 2021 | 1036 | 0.03 | Why? |
| Cross-Sectional Studies | 3 | 2019 | 53120 | 0.03 | Why? |
| Length of Stay | 2 | 2021 | 11042 | 0.03 | Why? |
| Immunohistochemistry | 1 | 2019 | 2275 | 0.03 | Why? |
| Pyridones | 1 | 2017 | 738 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2017 | 1444 | 0.03 | Why? |
| Europe | 2 | 2018 | 12702 | 0.03 | Why? |
| Sialic Acids | 1 | 2012 | 218 | 0.03 | Why? |
| Donor Selection | 1 | 2017 | 804 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.03 | Why? |
| Regression Analysis | 1 | 2018 | 2484 | 0.03 | Why? |
| Stomach | 1 | 2011 | 141 | 0.03 | Why? |
| Risk Assessment | 3 | 2020 | 25439 | 0.03 | Why? |
| Heart | 1 | 2019 | 1791 | 0.02 | Why? |
| Propensity Score | 1 | 2018 | 2690 | 0.02 | Why? |
| Drug Evaluation, Preclinical | 1 | 2021 | 3347 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2019 | 3786 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2017 | 3395 | 0.02 | Why? |
| Swine | 1 | 2017 | 3352 | 0.02 | Why? |
| Neutrophils | 2 | 2017 | 5476 | 0.02 | Why? |
| Glycosylation | 1 | 2012 | 1255 | 0.02 | Why? |
| Gene Expression | 1 | 2018 | 3332 | 0.02 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.02 | Why? |
| Cytokines | 2 | 2021 | 15010 | 0.02 | Why? |
| Endothelial Cells | 1 | 2017 | 2048 | 0.02 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 1454 | 0.02 | Why? |
| Antigens, CD | 1 | 2012 | 984 | 0.02 | Why? |
| Lung Diseases, Interstitial | 1 | 2018 | 1476 | 0.02 | Why? |
| Antifungal Agents | 1 | 2017 | 1828 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2021 | 6740 | 0.02 | Why? |
| Venous Thrombosis | 1 | 2021 | 2739 | 0.02 | Why? |
| Body Mass Index | 1 | 2018 | 4306 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2018 | 6543 | 0.02 | Why? |
| Transcriptome | 1 | 2018 | 3466 | 0.02 | Why? |
| Anti-Infective Agents | 1 | 2017 | 1766 | 0.02 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2017 | 51949 | 0.02 | Why? |
| Vero Cells | 1 | 2021 | 14117 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.02 | Why? |
| Cause of Death | 1 | 2017 | 4823 | 0.02 | Why? |
| Computer Simulation | 1 | 2018 | 4982 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 7868 | 0.02 | Why? |
| Disease Models, Animal | 1 | 2021 | 10998 | 0.02 | Why? |
| Pandemics | 2 | 2021 | 389249 | 0.02 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2012 | 2483 | 0.01 | Why? |
| Immune Evasion | 1 | 2012 | 2081 | 0.01 | Why? |
| Pulmonary Embolism | 1 | 2021 | 4775 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2021 | 10649 | 0.01 | Why? |
| Adrenal Cortex Hormones | 1 | 2018 | 6537 | 0.01 | Why? |
| Cell Line | 1 | 2017 | 12040 | 0.01 | Why? |
| Algorithms | 1 | 2018 | 7346 | 0.01 | Why? |
| Sepsis | 1 | 2018 | 3517 | 0.01 | Why? |
| Adaptive Immunity | 1 | 2012 | 2585 | 0.01 | Why? |
| Child | 2 | 2020 | 70012 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2021 | 88759 | 0.01 | Why? |
| HEK293 Cells | 1 | 2012 | 8394 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.01 | Why? |
| Protein Binding | 1 | 2012 | 11430 | 0.01 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.01 | Why? |
| Immunity, Innate | 1 | 2012 | 6570 | 0.01 | Why? |
| Mental Health | 1 | 2020 | 15770 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2012 | 11041 | 0.01 | Why? |
| United States | 1 | 2018 | 46150 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2011 | 43792 | 0.00 | Why? |
| Pneumonia, Viral | 1 | 2021 | 243684 | 0.00 | Why? |